Evidence map›Paper›PMID 41626721›Full record

ArticleHuman brain mapping2026

Investigating the Utility of Explainable Artificial Intelligence for Neuroimaging-Based Dementia Diagnosis and Prognosis.

Sophie A Martin, An Zhao, Jiongqi Qu, Phoebe Imms, Andrei Irimia, Frederik Barkhof, James H Cole, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Human brain mapping, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Sophie A MartinUCL Hawkes Institute, University College London, London, UK.ORCID https://orcid.org/0000-0003-3819-1634
An ZhaoUCL Hawkes Institute, University College London, London, UK.
Jiongqi QuUCL Hawkes Institute, University College London, London, UK.
Phoebe ImmsLeonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
Andrei IrimiaLeonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
Frederik BarkhofUCL Hawkes Institute, University College London, London, UK.
James H ColeUCL Hawkes Institute, University College London, London, UK.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MONICA G. RIVERA-MINDT · 2016 to 2026
$226.7M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
Alzheimer's Research UK ARUK-PPG2023B-016Department of Defense W81XWH-18-1-0413EPSRC Centre for Doctoral Training in Intelligent, Integrated Imaging in Healthcare EP/S021930/1NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG017265NIA NIH HHS P30AG017265NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086404NIA NIH HHS R01 AG079280NIA NIH HHS R01 AG079957NIA NIH HHS RF1 AG082201NIA NIH HHS T32 AG000037NIA NIH HHS U19 AG024904NIA NIH HHS U24 AG072122NIH HHS R01AG079957NIH HHS R01NS100973NIH HHS RF1AG082201NIH HHS T32AG000037-46NIH HHS U19AG024904NIHRNINDS NIH HHS R01 NS100973
6 · The paper itself

Abstract

Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve 'black box' models that can be difficult to trust. Explainable artificial intelligence (XAI) aims to provide insights into the model's decisions; however, choosing the most appropriate method is non-trivial and often context-specific. We used T1-weighted MRI to train models on two tasks: Alzheimer's disease (AD) classification (diagnosis) and predicting conversion from mild-cognitive impairment (MCI) to all-cause dementia (prognosis). We applied eleven XAI methods across two popular image classification architectures, producing visualisations of the most salient regions. We also propose a framework for interpreting explanations produced by different XAI methods and predictive models. Models achieved balanced accuracies of 81% and 67% for diagnosis and prognosis. XAI outputs highlighted brain regions relevant to AD with strong convergence across gradient-based techniques. LIME produced explanations that were most similar across architectures. Mean saliency enhanced MCI prognosis prediction when included as an additional input feature. XAI can be used to verify that models are utilising relevant features and to generate valuable measures for further analysis.

Indexed as

Alzheimer DiseaseArtificial IntelligenceBrainCognitive DysfunctionDementiaMagnetic Resonance ImagingNeuroimagingAgedFemaleHumansMalePrognosisdementiadiagnosisexplainable artificial intelligencemagnetic resonance imagingneuroimagingprognosisvision transformers

Identifiers

PMID41626721
PMCPMC12862880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.